PARP inhibitors
Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response
The collaboration between Mass General and Switzerland's Lunaphore will initially focus on developing a test for ovarian, breast, and prostate cancers.
Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development
The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting
The test is now approved as a CDx for advanced ovarian cancer patients considering Lynparza as a first-line maintenance treatment.
FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug
The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna.